{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:30:13Z","timestamp":1787016613372,"version":"build-2736575974"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"HHS | NIH | NIAID | Division of Intramural Research","award":["AI063503"],"award-info":[{"award-number":["AI063503"]}]},{"name":"HHS | NIH | NIAID | Division of Intramural Research","award":["HHSN272201700039I Task order A34 - 75N93019F00131"],"award-info":[{"award-number":["HHSN272201700039I Task order A34 - 75N93019F00131"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Ibrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer \u03b2-(1,3)-D-glucan by inhibiting the enzyme glucan synthase. We evaluated the\n                      <jats:italic>in vivo<\/jats:italic>\n                      efficacy of ibrexafungerp against pulmonary mucormycosis using an established murine model. Neutropenic mice were intratracheally infected with either\n                      <jats:italic>Rhizopus delemar<\/jats:italic>\n                      or\n                      <jats:italic>Mucor circinelloides<\/jats:italic>\n                      . Treatment with placebo (diluent control), ibrexafungerp (30 mg\/kg, PO BID), liposomal amphotericin B (LAMB 10 mg\/kg IV QD), posaconazole (PSC 30 mg\/kg PO QD), or a combination of ibrexafungerp plus LAMB or ibrexafungerp plus PSC began 16 h post-infection and continued for 7 days for ibrexafungerp or PSC and through day 4 for LAMB. Ibrexafungerp was as effective as LAMB or PSC in prolonging median survival (range: 15 days to &gt;21 days) and enhancing overall survival (30%\u201365%) vs placebo (9 days and 0%;\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) in mice infected with\n                      <jats:italic>R. delemar<\/jats:italic>\n                      . Furthermore, median survival and overall percent survival resulting from the combination of ibrexafungerp plus LAMB were significantly greater compared to all monotherapies (\n                      <jats:italic>P<\/jats:italic>\n                      \u2264 0.03). Similar survival results were observed in mice infected with\n                      <jats:italic>M. circinelloides<\/jats:italic>\n                      . Monotherapies also reduce the lung and brain fungal burden by ~0.5\u20131.0log\n                      <jats:sub>10<\/jats:sub>\n                      conidial equivalents (CE)\/g of tissue vs placebo in mice infected with\n                      <jats:italic>R. delemar<\/jats:italic>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05), while a combination of ibrexafungerp plus LAMB lowered the fungal burden by ~0.5\u20131.5log\n                      <jats:sub>10<\/jats:sub>\n                      CE\/g compared to placebo or any of the monotherapy groups (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.03). These results are promising and warrant continued investigation of ibrexafungerp as a novel treatment option against mucormycosis.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1128\/aac.01545-23","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T09:00:26Z","timestamp":1711962026000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B"],"prefix":"10.1128","volume":"68","author":[{"given":"Teclegiorgis","family":"Gebremariam","sequence":"first","affiliation":[{"name":"The Lundquist Institute at Harbor\u2014University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sondus","family":"Alkhazraji","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor\u2014University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyou","family":"Gu","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor\u2014University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Najvar","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyna","family":"Borroto-Esoda","sequence":"additional","affiliation":[{"name":"Scynexis Inc., Jersey City, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott G.","family":"Filler","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor\u2014University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA"},{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":true,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-8530","authenticated-orcid":true,"given":"Ashraf S.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"The Lundquist Institute at Harbor\u2014University of California at Los Angeles (UCLA) Medical Center, Torrance, California, USA"},{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001653691"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/339202"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/422723"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.556-569.2005"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.13.2.236"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/432579"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30312-3"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000549"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2016.03.029"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.830-832.2005"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01458-07"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/589857"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01124-08"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00628-08"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01601-08"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02819-15"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof7040313"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00313-13"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00178-20"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.721-727.2005"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01545-23","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01545-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:02:48Z","timestamp":1714640568000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01545-23"}},"subtitle":[],"editor":[{"given":"Andreas H.","family":"Groll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.1128\/aac.01545-23"],"URL":"https:\/\/doi.org\/10.1128\/aac.01545-23","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"2023-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01545-23"}}